Q3 2024 ALK-Abello A/S Earnings Call Transcript
Key Points
- Alk-Abello AS (AKBLF) reported an 18% organic revenue growth across regions and product lines in Q3.
- The company successfully increased its EBIT margin by 10 percentage points year-on-year, from 13% to 23%.
- Sales of the adrenaline auto-injector, JEXT, more than doubled, recovering from last year's supply shortages.
- The implementation of the Energy Plus strategy is progressing well, with new initiatives in the allergy space.
- Alk-Abello AS (AKBLF) confirmed its full-year outlook, expecting 14-16% top-line growth and an EBIT margin of 19-21%.
- Growth in North America was soft, with only a 3% increase in sales.
- Sales of other products in North America, such as diagnostics and Pre-Pen, decreased by 4%.
- The integration of Pre-Pen operations has been completed, but sales continue to perform below expectations.
- The company faces challenges in the US market, particularly with sluggish performance in some business segments.
- There are anticipated additional one-off costs related to the revisions of plans and activities in China.
Hello, everyone and welcome to this presentation of A LKSQ three results. Thank you all for joining the call. And let's turn to slide number two with an intro to the agenda and the speakers.
My name is Per Plotnikof. I'm head of Investor relations and with me today are CEO Peter Helling and Co Klaus Sten.
We will be sharing a couple of highlights from Q3. We'll take a closer look at markets, product trends and financials. We'll also provide an update on the plus strategy implementation before we turn to the full year outlook. As usual, we will end the presentation with a Q&A session to get started. I'll hand over to Peter and Slide 3, please.
/- -
Thank you Pierre and thank you all for joining this call. Q3 was another solid quarter for A LK.
We delivered 18% organic revenue growth across regions and product lines. And we are particularly encouraged by the robust growth rates for Tapti 29% on global scale and 27% in our main
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
